Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.

@article{Kerlan2013UseOI,
  title={Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.},
  author={V. Kerlan and D. Gouet and M. Marre and {\'E}. Renard},
  journal={Annales d'endocrinologie},
  year={2013},
  volume={74 5-6},
  pages={
          487-90
        }
}
  • V. Kerlan, D. Gouet, +1 author É. Renard
  • Published 2013
  • Medicine
  • Annales d'endocrinologie
  • Insulin degludec is a new basal insulin analogue with an ultra-long duration of action that provides a flat and stable action profile with a duration of action greater than 42 hours. Two clinical trials comparing insulin degludec and insulin glargine in basal-bolus therapy have recently been published. Both were 52-week, multicentre, randomised (3:1), treat-to-target trials in patients already using insulin. In both type 1 (n=629) and type 2 diabetes (n=1006), insulin degludec was non-inferior… CONTINUE READING
    2 Citations
    Glycemic Management in Adults With Type 1 Diabetes.
    • 10
    • PDF
    Patient Assessment in Clinical Pharmacy
    • Highly Influenced
    • PDF

    References

    SHOWING 1-10 OF 18 REFERENCES
    A review of human and analogue insulin trials.
    • S. Gough
    • Medicine
    • Diabetes research and clinical practice
    • 2007
    • 119
    Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
    • 310
    • PDF
    Hypoglycemia: An overview of fear of hypoglycemia, quality-of-life, and impact on costs
    • 149
    The impact of non-severe hypoglycemic events on work productivity and diabetes management.
    • 229